Precision Immunotherapy and Bladder Cancer Treatment Are One Call Away
Call Now
Early Stage, Late Stage, and Metastatic Bladder Cancer Treatment
Options
Advanced Immunotherapy and Bladder Cancer Treatments for all
Types and Stages of Disease
Wouldn’t you prefer to treat your bladder cancer without having to surgically remove it? At Envita Medical
Centers, a world-class integrative Center of Excellence for precision oncology, located in Scottsdale, Arizona,
we aim to help cancer patients retain their organs while working towards a successful recovery. Our
precision-targeted protocols are designed to treat the disease and provide patients with more options, rather
than limiting them to relying on drainage bags or complicated reconstruction surgeries for urinary diversion as
part of their bladder cancer treatment.
Envita’s integrative physicians break away from the limited treatment options in standard oncology, to bring
the latest
developments in cancer research into our personalized precision oncology bladder cancer treatment program. We
utilize a
powerful combination of cutting-edge conventional medicine with research-based natural therapies to provide
personalized
precision integrative medicine.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
Our personalized precision oncology treatments proved extremely beneficial for Maynard, as our team of doctors
custom-builds a protocol to attack each patient’s cancerous cells from all possible angles. Our precision algorithms,
developed as a result of our extensive clinical experience in treating patients who were failing to respond to care in
other standard cancer treatment centers, form the basis of these protocols.
Envita Medical Centers Medical Team
Physicians with MD, MD(h), and NMD medical
licenses, including certified oncologists, and certified interventional radiologists,
striving to provide the latest cancer innovations
22
Pharmacists specializing in integrative agents
7
Nurses trained in precision treatment delivery
40+
In our clinical experience of over 20 years, we have been able to optimize results for early-stage bladder tumor
patients, as well as stage IV metastatic bladder cancer patients, many of whom were limited to palliative care after
failing to respond to standard regimens. We utilize advanced proprietary treatments, like CIPI™ (Chemo Immuno
Precision
Injections), GTFC™ (Genetically Targeted Fractionated Chemotherapy), and personalized immunotherapies, to go beyond
the
scope of standard treatments, such as, radical cystectomy, transurethral resection, radiation therapy, intravesical
BCG
(Bacillus Calmette-Guérin), or systemic chemotherapy. Our personalized protocols are aimed at precision-targeting the
disease and offering supportive care to boost the immune system, which is a critical part of a cancer patient’s
holistic
healthcare for reducing chances of recurrence.
Our personalized precision oncology bladder cancer treatments are based on real-time bioinformatic data,
which helps in
customizing a truly comprehensive treatment plan with proactive interventions. These interventions are
designed to
effectively treat the disease and reduce chances of its recurrence, which is considered one of the major
challenges of
bladder cancer treatment.
This article covers the following facts about bladder cancer, including:
How Envita Revolutionizes Bladder Cancer Care
Studies show
that nearly three-fourths of patients diagnosed with high-risk bladder cancer will recur, progress, or die within
ten years of their diagnosis [1]. In an effort to overcome such challenges, we go beyond the NCCN (National
Comprehensive Cancer Network) guidelines, typically followed in most standard cancer treatment centers.
These one-size-fits-all protocols generally determine care based on patients’ cancer type and stage, but these
parameters alone may not be enough to guide treatment. The lack of a better understanding of each patient’s cancer
explains why everyone with the same type and stage of bladder cancer does not respond similarly to the same treatment.
Cancer is a disease of genetic mutations, not tissue types or organs, which highlights the need for precision oncology
to personalize treatment protocols for effectively targeting the disease.
According to the National Cancer Institute’s report
based on patient outcomes across standard cancer centers, which
typically follow the NCCN guidelines, the 5-year relative survival rate of bladder cancer drops down to a dismal
8.3% when it spreads to distant
parts of the body.
Envita’s Advanced and Personalized Treatment Plans for Bladder Cancer
To help our patients, we break through the standard templatized NCCN guidelines, which typically allow access to
precision oncology as a follow-up to failed first-line treatments. However, this delay may lead to catastrophic
consequences, and to reduce the chances of such consequences we offer precision oncology options to every patient
right
at the beginning of care, irrespective of whether they have Muscle Invasive Bladder Cancer (MIBC) or Non Muscle
Invasive
Bladder Cancer (NMIBC).
Access to Precision Oncology Treatments for Every Patient at Envita
At Envita, we not only precision-target the unique set of causes responsible for the growth and spread of disease in
each individual patient, but we also reactivate their immune system to help prevent cancer recurrence. In our clinical
opinion, precision oncology widens the tool kit of options for each and every bladder cancer patient, irrespective of
their stage or type of disease.
Envita Precision Algorithm vs. Standard Oncology Precision Testing
Envita Medical Centers
Standard Oncology Precision Testing
RNA Transcriptome Genes
Envita Medical Centers:20,000+
Standard Oncology:Unchecked
SNV/CNV Genes
Envita Medical Centers:452
Standard Oncology:309
Rearrangements/Fusion Genes
Envita Medical Centers:51
Standard Oncology:27
Microsatellite Instability (MSI)
Envita Medical Centers:Checked
Standard Oncology:Checked
Tumor Mutation Burden (TMB)
Envita Medical Centers:Checked
Standard Oncology:Checked
BRCA 1/2
Envita Medical Centers:Checked
Standard Oncology:Checked
Immunohistochemistry
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Chemosensitivity
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Concurrent Liquid Biopsy
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Exosomal miRNA Analysis
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Circulating Tumor Cells Enumeration
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Pharmacogenomics
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Individualized Therapy Recommendation
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Carcinogenic Exposure - Root Causes
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Inflammation Markers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Metabolic Target Drivers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
The handful of patients who get access to precision oncology in standard cancer treatment centers receive a
watered-down
version of Envita’s detailed personalized precision oncology Bladder Cancer Treatment program. Checking and analyzing
a
greater number of factors, which could potentially influence your bladder cancer’s growth and spread, helps us to
design
a comprehensive treatment plan for each individual patient, without compromising on their immune system.
New Treatment Approach to Overcome the Limitations of Standard Treatments and Clinical Trials
At Envita, we follow the N-of-1
clinical trial model of treatment to personalize care for each individual patient, by taking into account the
unique set of factors
affecting their cancer [2]. This innovative approach helps to overcome certain challenges of large
sample
clinical trials, which are more focused on testing the efficacy of new drugs and therapies rather than going
into the details of each
patient’s unique cancer and its microenvironment. At Envita, we follow a four-step process to design a unique medical
blueprint for each individual bladder cancer patient, with the aim of improving their quality of life, increasing
their
longevity, and reducing toxicities and side effects.
Step 1
Genomic Identification to Address the Unique Risk Factors of Each Cancer Patient
According to the American Cancer
Society, a risk factor is anything that affects your chance of getting a disease, but once you are diagnosed
with the disease,
identifying these unique set of risk factors helps to strike at the disease core. We utilize a detailed genomic analysis and proprietary tests for a
comprehensive understanding of the root causative factors of each patient’s cancer. This
bioinformatics data is crucial because it helps us design a personalized and precision-targeted treatment plan for
each
individual bladder cancer patient.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
Scientific studies
also support the fact that next-generation sequencing of nonmuscle-invasive bladder cancer (NMIBC) reveals potential
biomarkers and rational therapeutic targets [3], which is what we aim to identify for tailoring your care. NMIBC
constitutes around three-quarters of the disease burden of bladder cancer, and typically does not invade the bladder
wall, but it has the potential to progress. To treat existing disease burden, reduce chances of progression, and
proactively treat early signs of disease growth in all stages and types of bladder cancer, we custom-develop treatment
plans for each individual bladder cancer patient.
Step 2
Immuno Targeting to Reduce Chances of Recurrence and Metastasis
At Envita, we have been pioneering in the field of personalized immunotherapies, going way beyond intravesical BCG and
standard immune checkpoint inhibitors, like pd-1 and pd-l1. We believe that the
immune system is the first and last line of defense against cancer, which is why we work towards utilizing its innate
ability in not only tackling the disease, but in identifying and proactively treating early signs of micro metastases
or
recurrence.
Medical studies
show that incomplete resection
and tumour cell re-implantation seem to dominate as the cause of early bladder urothelial
cancer recurrence [4], but with our advanced Ultra Analytes Liquid Biopsy we aim to examine the circulating tumor
cells
(CTCs) in the patient’s blood stream. Investigating these CTCs helps us to identify early signs of micro metastases
and
treat the cancer in its trajectory, without having to wait for the patient to experience symptoms of recurrence or
metastases. The most common sites of metastasis
from bladder cancer are the lymph nodes, bones, lung, liver, and peritoneum [5].
Ultra Analytes Liquid Biopsy
Ultra Analytes Liquid Biopsy is deployed to identify targeted immunotherapy options to help get your
immune system working properly again.
Learn more
about
Immunotherapy
Step 3
Personalized Drug Design to Debulk Tumors and Potentiate Responses
Irrespective of the type and stage of bladder cancer, we include varied combinations of FDA (Food and Drug
Administration) approved drugs, repurposed drugs, and custom-compounded adjuvants for our patients. These
combinations
are determined based on each patient’s unique biomarker expressions, revealed through our detailed proprietary
tests. In
our clinical experience, not all biomarkers can be impacted with the existing drugs available on the market,
which is
why we custom-compound adjuvants at our personalized drug design includes a powerful
combination of FDA (Food and Drug Administration) approved drugs, repurposed drugs, and our custom
compounded adjuvants, manufactured at our in-house pharmacy.
FDA Approved Drugs
Optimized for your cancer mutations.
Repurposed Drugs
Off-label use of approved medications
Custom Compounded Adjuvants
Genetically typed for each patient.
Our custom-compounded adjuvants are based on advanced phytotherapeutics, and the latest studies point towards decreased drug resistance of
bladder cancer using phytochemicals treatment [6]. Naturally occurring
compounds from plants known as phytochemicals, serve as vital resources for novel drugs and are also sources for cancer
therapy[7].
These phytochemicals often act via regulating molecular pathways which are implicated in growth and progression of
cancer. The specific mechanisms include increasing antioxidant status, carcinogen inactivation, inhibiting
proliferation, induction of cell cycle arrest and apoptosis; and regulation of the immune system.
These powerful treatments can be combined with your primary treatment, utilized as neoadjuvant therapies to debulk
bladder tumors, or as adjuvant therapies after primary treatment to attack remaining cancer cells. At Envita, we also
adjust the dosage of standard chemotherapy drugs and other FDA approved and repurposed drugs to suit the specific rate
of metabolism of each individual patient. Our personalized drug
design approach is aimed at potentiating patient responses, while reducing toxicities and the chances of side
effects,
typically associated with conventional bladder cancer treatment.
Precision Deployment to Provide the Next Level in Bladder Cancer Care
Envita’s proprietary precision deployment mechanisms, like GTFC™ and CIPI™, are designed to take cancer care to the
next
level, by overcoming challenges of standard bladder cancer treatments, such as, Transurethral resection of bladder
tumor
(TURBT), cystectomy, maximum therapeutic dose untargeted chemotherapy, and radiation. As part of TURBT, an electric
wire
loop is utilized to eliminate the cancerous cells in the bladder, while cystectomy involves partial or complete
removal
of the bladder. Both these procedures may be followed by chemotherapy and depending on the extent of cystectomy,
patients often end up compromising on their quality of life. However, here at Envita, our aim is to help you recover
holistically without compromising on your quality of life.
Depending on your type and stage of bladder cancer, the following proprietary precision deployment mechanisms may be
used one or more times or in combination with other personalized therapies:
CIPI™ (Chemo Immuno Precision Injection)
CIPI™ is our proprietary interventional radiology procedure for precision tumor embolization. This
groundbreaking,
minimally invasive technology utilizes a catheter, thinner than a strand of hair, to deploy personalized chemo
and
immunotherapy adjuvant agents directly at the site of the tumor. With CIPI™, we aim to destroy the malignant cancer
cells, deactivate tumors, and shut down its blood supply. The neoantigens
released by the deactivated tumor stimulates the immune system to search and destroy cancerous cells, elsewhere
in the
body, minimizing the likelihood of recurrences, which is considered one of the major challenges of bladder
cancer
treatment.
Envita's CIPI™ vs. Standard Surgery
Envita Medical Centers
Standard Surgery
Minimally invasive so it can be performed within 40-50 minutes, without the need for large surgical
incisions.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Can be performed multiple times, even at close intervals, because there is minimal risk of post-op
complications.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
No need for general anesthesia, reducing the health risks that can result from being put into a
medically induced coma to perform an invasive surgery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Faster recovery time as compared to traditional surgery, due to the minimally invasive administration.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Provides direct tumor targeting, which delivers patient-specific genomic agents into the tumor.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Causes a systemic immune response where the immune system is reactivated to find and attack other
metastatic cancer sites in the body.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Performed by highly trained medical professionals in an outpatient setting, so there is no need of
hospital stays for recovery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
GTFC™ has proven to be beneficial for many bladder cancer patients because this proprietary low dose chemotherapy is
based on a detailed analysis of each patient’s bioinformatics. It takes the guesswork out of your treatment by
utilizing
chemo
drugs with the maximum potential of cancer kill, suitable for each patient’s unique cancer microenvironment and their
disease burden.
GTFC™ is administered intravenously and it is designed
to
precisely-target the cancerous cells, while reducing impact to the
surrounding healthy cells. As a result, most of our patients do not experience severe side effects, such as nausea,
hair
loss, and fatigue, typically associated with standard untargeted chemotherapy.
Envita's GTFC™ vs. Standard Chemotherapy
Envita Medical Centers
Standard Chemotherapy
Helps to improve chemotherapy delivery to the tumor using a "Trojan Horse" delivery mechanism.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses genetic molecular profiling to understand all the facets of each patient's specific cancer.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses targeted treatment to enhance the mechanism of cancer kill.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses microdosed (fractionated) chemotherapies, reducing the chances of impacting healthy cells.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Minimizes toxicity to normal cells, lowering the chance of side-effects related to administration.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses patient-specific supportive immunotherapy to strengthen the immune system.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Aims to reduce multidrug resistance by administering 10 - 20% of the medication delivered in maximum dose
chemo.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Allows custom-compounded medications to be readministered in tandem to suit each patient's individual cancer
mutations.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
The following are some of the common types of bladder cancer with their different variations:
Urothelial Carcinoma (also called Transitional Cell Carcinoma): Starts from the urothelial cells lining
the inside of the bladder. These urothelial cells also line the ureters,
urethra, and other parts of the urinary tract, which explains why urothelial cancers can also originate in
these other
parts, close to the bladder. Urothelial Carcinoma is one of the most common types of bladder cancer. According
to the American Cancer Society
Journals, UC originates less
commonly from the upper urinary tract (ie, renal pelvis, ureter, and urethra). Tumors that invade
the detrusor muscle are referred to as muscle-invasive bladder cancers (MIBCs) and have a higher propensity
to spread to
lymph nodes and other organs. Nonmuscle-invasive bladder cancers (NMIBCs) comprise distinct entities,
including
carcinoma in situ (CIS), papillary noninvasive tumors, and papillary tumors invading the lamina propria.
Squamous cell carcinoma: This type of bladder cancer arises from the thin, flat cells that can form in
the bladder lining in response to chronic
irritation or infection. Squamous cell carcinoma accounts for a small percentage of bladder cancer cases.
Adenocarcinoma: This type of bladder cancer is relatively rare, accounting for around 1% to 2% of
cases. Adenocarcinoma develops in the
glandular cells that produce mucus in the bladder lining.
Small cell carcinoma: Small cell carcinoma of the bladder is a rare and high grade bladder cancer. It
is similar to small cell lung cancer and
tends to grow and spread quickly.
Symptoms of Bladder Cancer
If you experience any of the following symptoms, your doctor may recommend urine tests, imaging tests, or
cystoscopy, to
diagnose whether you have bladder cancer:
Envita’s highly skilled physicians undergo rigorous training exceeding 1,500 hours to seamlessly integrate into our
tailored precision oncology program. Our collaborative team, including oncologists, interventional radiologists,
researchers, and pharmacists, work to ensure that patients benefit from their collective knowledge and experience.
If
you or your loved ones have any questions regarding bladder cancer or any other cancer, please contact us at:
866-830-4576. May God bless you on your journey to healing.
References
[1] Chamie K, Litwin MS, Bassett JC, et al. Recurrence of high-risk bladder cancer: a population-based
analysis. Cancer.
2013;119(17):3219-3227. doi:10.1002/cncr.28147
[2] Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate
strategy for
individualizing medicine?. Per Med. 2011;8(2):161-173. doi:10.2217/pme.11.7
[3] Butterfield A, Gupta S. Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards
personalized
medicine for a superficial bladder tumor. Transl Androl Urol. 2017;6(6):1198-1202.
doi:10.21037/tau.2017.11.27
[4] Bryan RT, Collins SI, Daykin MC, et al. Mechanisms of recurrence of Ta/T1 bladder cancer. Ann R Coll Surg
Engl.
2010;92(6):519-524. doi:10.1308/003588410X1266419207693
[5] Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD. Metastatic pattern of
bladder
cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011;196(1):117-122.
doi:10.2214/AJR.10.5036
[6] Cho CJ, Yu CP, Wu CL, Ho JY, Yang CW, Yu DS. Decreased drug resistance of bladder cancer using
phytochemicals
treatment. Kaohsiung J Med Sci. 2021;37(2):128-135. doi:10.1002/kjm2.12306
[7] Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in Cancer Treatment: From
Preclinical
Studies to Clinical Practice [published correction appears in Front Pharmacol. 2020 Feb 28;11:175]. Front
Pharmacol.
2020;10:1614. Published 2020 Jan 28. doi:10.3389/fphar.2019.01614
Our team is ready to help you get your life back! Please enter your contact information and a Patient Care
Expert will contact you shortly. If you would rather speak now, please give us a call at 1-866-830-4576.
